$9.61
▼ -0.1% Today
as of Sep 4, 16:45 ET
Last 30 days
Recent Press Releases & News
Adma Biologics (ADMA) Down 4.8% Since Last Earnings Report: Can It Rebound?
ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness
ADMA Biologics Inc (ADMA) (Q2 2026) Earnings Call Highlights: Ascentiv Surges 24% as Gross ...
Overview
52-week range
$7.21
$20
18% of range
Avg surprise (last 2)
-2.7%
Avg reaction (last 2)
+0.2%
50% positive
Latest IV / EM
67%
EM ±10.4% · $10 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $0.16 | — | — | — | — | financials |
| Wed May 6, 2026 | Mar/2026 | $0.19 | — | — | +35.7% | -1.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.15 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $0.15 | $0.14 | +7.1% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $0.14 | $0.16 | -12.5% | — | +2.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $0.15 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.13 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.08 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.01 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.03 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.03 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $124M | $114M | — | $134M | $122M | $115M | — | $120M |
| Cost of revenue | $38M | $34M | — | $59M | $55M | $54M | — | $60M |
| Gross profit | $86M | $81M | — | $76M | $67M | $61M | — | $60M |
| Operating income | $52M | $58M | — | $51M | $43M | $35M | — | $40M |
| Net income | $38M | $45M | — | $36M | $34M | $27M | — | $36M |
| EPS (diluted) | $0.16 | $0.19 | — | $0.15 | $0.14 | $0.11 | — | $0.15 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $136M | $138M | $88M | $61M | $90M | $72M | $103M | $87M |
| Inventory | $239M | $222M | $206M | $197M | $191M | $172M | $170M | $172M |
| Total current assets | $528M | $511M | $467M | $403M | $400M | $352M | $331M | $318M |
| Total assets | $684M | $665M | $624M | $569M | $558M | $511M | $489M | $391M |
| Long-term debt | $193M | $194M | $69M | $70M | — | — | $72M | — |
| Total liabilities | $276M | $275M | $147M | $138M | $160M | $137M | $140M | $159M |
| Total equity | $408M | $390M | $477M | $431M | $398M | $373M | $349M | $232M |